跳到正文
原文
U.S. FDA· @FDA · X·· 21 天前AI 评分20
AI 导读

现代化FDA的审评流程始于倾听。代理局长Kyle Diamantas周一在#NORDSummit上与@RareDiseases一起讨论了患者声音如何成为构建罕见病疗法适用框架的核心。

正文

Modernizing FDA's review process starts with listening. Acting Commissioner Kyle Diamantas joined @RareDiseases at the #NORDSummit Monday to discuss how patient voices are central to building a fit-for-purpose framework for #RareDisease therapies.

引用National Organization for Rare Disorders (NORD)@RareDiseases
Acting @FDA Commissioner Kyle Diamantas, @FDA_KyleD, sat down for a fireside chat with #NORD President and CEO Pam Gavin to kick off the 2026 #NORDSummit, where he shared that the #FDA is committed to modernizing its review process and is relying on #RareDisease patient voices to help shape its fit-for-purpose regulatory framework. We appreciated the opportunity to break down what that will entail, and we're excited to be a partner in this crucial, timely mission.
在 X 查看被引用的帖子

来源:U.S. FDA · x.com